DK1004572T3 - Aminer som inhibitorer af TNF alpha - Google Patents
Aminer som inhibitorer af TNF alphaInfo
- Publication number
- DK1004572T3 DK1004572T3 DK00200498T DK00200498T DK1004572T3 DK 1004572 T3 DK1004572 T3 DK 1004572T3 DK 00200498 T DK00200498 T DK 00200498T DK 00200498 T DK00200498 T DK 00200498T DK 1004572 T3 DK1004572 T3 DK 1004572T3
- Authority
- DK
- Denmark
- Prior art keywords
- amines
- inhibitors
- tnf alpha
- phthaloylisoglutamine
- phthaloylglutamine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
- C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8751093A | 1993-07-02 | 1993-07-02 | |
EP94921439A EP0706521B1 (de) | 1993-07-02 | 1994-07-01 | Imide als tnf alpha inhibitoren |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1004572T3 true DK1004572T3 (da) | 2006-07-10 |
Family
ID=22205623
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK94921439T DK0706521T3 (da) | 1993-07-02 | 1994-07-01 | Imider som TNF-alfa-inhibitorer |
DK00200498T DK1004572T3 (da) | 1993-07-02 | 1994-07-01 | Aminer som inhibitorer af TNF alpha |
DK00200491T DK1004580T3 (da) | 1993-07-02 | 1994-07-01 | Imider som inhibitorer af TNF-alfa |
DK00200492T DK1004581T3 (da) | 1993-07-02 | 1994-07-01 | Fremgangsmåde til fremstilling af thalidomid |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK94921439T DK0706521T3 (da) | 1993-07-02 | 1994-07-01 | Imider som TNF-alfa-inhibitorer |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00200491T DK1004580T3 (da) | 1993-07-02 | 1994-07-01 | Imider som inhibitorer af TNF-alfa |
DK00200492T DK1004581T3 (da) | 1993-07-02 | 1994-07-01 | Fremgangsmåde til fremstilling af thalidomid |
Country Status (20)
Country | Link |
---|---|
US (1) | US5463063A (de) |
EP (5) | EP1477486A3 (de) |
JP (5) | JP3971794B2 (de) |
KR (1) | KR100401290B1 (de) |
AT (4) | ATE225344T1 (de) |
AU (1) | AU687843B2 (de) |
CA (3) | CA2626178A1 (de) |
CZ (2) | CZ1096A3 (de) |
DE (4) | DE69434029T2 (de) |
DK (4) | DK0706521T3 (de) |
ES (4) | ES2278574T3 (de) |
FI (2) | FI114984B (de) |
HK (3) | HK1025769A1 (de) |
HU (1) | HUT75312A (de) |
NZ (3) | NZ329258A (de) |
PL (1) | PL180377B1 (de) |
PT (4) | PT1004580E (de) |
RU (1) | RU2174516C2 (de) |
SK (1) | SK166595A3 (de) |
WO (1) | WO1995001348A2 (de) |
Families Citing this family (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US5686436A (en) * | 1993-05-13 | 1997-11-11 | Hiv Diagnostics, Inc. | Multi-faceted method to repress reproduction of latent viruses in humans and animals |
HU226558B1 (en) * | 1994-12-30 | 2009-03-30 | Celgene Corp | Immunotherapeutic imides/amides and their use for reducing levels of tnfalpha |
US5703098A (en) * | 1994-12-30 | 1997-12-30 | Celgene Corporation | Immunotherapeutic imides/amides |
US5801195A (en) * | 1994-12-30 | 1998-09-01 | Celgene Corporation | Immunotherapeutic aryl amides |
US6429221B1 (en) * | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
US5728845A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic nitriles |
US5728844A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
US5658940A (en) * | 1995-10-06 | 1997-08-19 | Celgene Corporation | Succinimide and maleimide cytokine inhibitors |
DE19548378A1 (de) * | 1995-12-27 | 1997-07-03 | Bran & Luebbe | Verfahren und Gerätekombination zur Herstellung der Vergleichbarkeit von Spektrometermessungen |
DE69700616T2 (de) * | 1996-07-02 | 2000-03-16 | Nisshin Flour Milling Co | Imid derivate |
ATE530542T1 (de) * | 1996-07-24 | 2011-11-15 | Celgene Corp | Amino substituierte 2-(2,6-dioxopiperidin-3-yl)- phthalimide zur verringerung der tnf-alpha-stufen |
US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
EP2177517B1 (de) * | 1996-07-24 | 2011-10-26 | Celgene Corporation | Amino substituierte 2-(2,6-Dioxopiperidin-3-yl)-phthalimide zur Verringerung der TNF-Alpha-Stufen |
HU228769B1 (en) * | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
EP0915700B1 (de) * | 1996-08-05 | 2006-03-22 | Myriad Genetics, Inc. | Verwendung von beta-blatt mimetika als protease und kinase hemmer und alshemmer eines transkriptionsfaktors |
EP1661566A3 (de) * | 1996-08-05 | 2008-04-16 | Myriad Genetics, Inc. | Verwendung von Beta-Blatt Mimetika als Protease und Kinase Hemmer sowie als Hemmer eines Transkriptionsfaktors |
WO1998006692A1 (en) * | 1996-08-12 | 1998-02-19 | Celgene Corporation | Novel immunotherapeutic agents and their use in the reduction of cytokine levels |
DE19703763C1 (de) * | 1997-02-01 | 1998-10-01 | Gruenenthal Gmbh | Thalidomidanaloge Verbindungen aus der Klasse der Piperidin-2,6-Dione |
KR19980074060A (ko) * | 1997-03-21 | 1998-11-05 | 김윤배 | 신규한 치환된 3,4-디알콕시페닐 유도체 |
KR100716475B1 (ko) * | 1997-07-31 | 2007-05-10 | 셀진 코오퍼레이션 | 치환된 알카노하이드록삼산 및 TNFα 농도 감소화 방법 |
US6831057B2 (en) | 1997-10-28 | 2004-12-14 | The University Of North Carolina At Chapel Hill | Use of NF-κB inhibition in combination therapy for cancer |
SK7382000A3 (en) * | 1997-11-18 | 2000-12-11 | Celgene Corp | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines, pharmaceutical composition containing the same and their use |
US5955476A (en) * | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
BR9908811A (pt) | 1998-03-16 | 2000-12-05 | Celgene Corp | Composto, composição farmacêutica e seu uso no tratamento de mamìferos |
US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
US7629360B2 (en) * | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
DE19948126A1 (de) * | 1999-10-06 | 2001-04-12 | Max Delbrueck Centrum | Pharmazeutisches Mittel zur Behandlung von Kachexie und/oder kardiogenem Schock |
US6667316B1 (en) * | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US6326388B1 (en) * | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
US6670358B2 (en) * | 2000-05-16 | 2003-12-30 | Cephalon, Inc. | Substituted thioacetamides |
US8030343B2 (en) * | 2000-06-08 | 2011-10-04 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
US6555581B1 (en) | 2001-02-15 | 2003-04-29 | Jones Pharma, Inc. | Levothyroxine compositions and methods |
ES2172474B1 (es) * | 2001-03-01 | 2004-01-16 | Fundacion Universitaria San Pa | Derivados de glutarimida como agentes terapeuticos. |
AU2002323063B2 (en) * | 2001-08-06 | 2007-11-08 | Entremed, Inc. | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs |
US7498171B2 (en) * | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
NZ570777A (en) * | 2002-05-17 | 2009-04-30 | Celgene Corp | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
US20100129363A1 (en) * | 2002-05-17 | 2010-05-27 | Zeldis Jerome B | Methods and compositions using pde4 inhibitors for the treatment and management of cancers |
GB0215392D0 (en) * | 2002-07-03 | 2002-08-14 | Glaxo Group Ltd | Chemical compounds |
NZ539534A (en) * | 2002-10-15 | 2008-06-30 | Celgene Corp | Selective cytokine inhibitory drugs for treating myelodysplastic syndrome |
US20040087558A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
US7776907B2 (en) * | 2002-10-31 | 2010-08-17 | Celgene Corporation | Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
AU2003290652B2 (en) | 2002-11-06 | 2008-06-19 | Celgene Corporation | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
KR20050072790A (ko) * | 2002-11-06 | 2005-07-12 | 셀진 코포레이션 | 골수증식 질환의 치료 및 관리를 위한 선택적 시토킨 억제약물의 사용 방법 및 이를 포함하는 조성물 |
MXPA05005161A (es) * | 2002-11-18 | 2005-07-22 | Celgene Corp | Metodos de utilizacion y composiciones que comprenden (-)3- (3, 4-dimetoxi- fenil)-3 -(1-oxo -1, 3-dihidro- isoindol- 2-il)- propionamida. |
BR0316259A (pt) * | 2002-11-18 | 2005-10-04 | Celgene Corp | Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto |
JP2006519875A (ja) * | 2003-03-06 | 2006-08-31 | セルジーン・コーポレーション | 中枢神経系障害を治療するための選択的サイトカイン阻害剤 |
US20040175382A1 (en) * | 2003-03-06 | 2004-09-09 | Schafer Peter H. | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
KR101138064B1 (ko) * | 2003-03-12 | 2012-04-23 | 셀진 코포레이션 | N-알킬-히드록삼산-이소인돌릴 화합물 및 그의 제약학적용도 |
CN100427465C (zh) * | 2003-03-12 | 2008-10-22 | 细胞基因公司 | N-烷基-异羟肟酸-异吲哚基化合物及其药物用途 |
WO2004083163A1 (ja) * | 2003-03-17 | 2004-09-30 | Ube Industries, Ltd. | 3-アミノ-3-アリールプロピオン酸n-アルキルエステル及びその製造方法並びに光学活性3-アミノ-3-アリールプロピオン酸及びその対掌エステルの製造方法 |
CN100398534C (zh) * | 2003-09-15 | 2008-07-02 | 天津和美生物技术有限公司 | 合成酞胺哌啶酮及其衍生物的方法 |
CA2543132A1 (en) * | 2003-10-23 | 2005-05-19 | Celgene Corporation | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
US20050142104A1 (en) * | 2003-11-06 | 2005-06-30 | Zeldis Jerome B. | Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders |
AU2005220728B2 (en) | 2004-02-27 | 2009-08-06 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
CN1972686A (zh) * | 2004-04-14 | 2007-05-30 | 细胞基因公司 | 选择性细胞因子抑制药在髓发育不良综合征中的用途 |
JP2007533760A (ja) * | 2004-04-23 | 2007-11-22 | セルジーン・コーポレーション | 肺高血圧症を治療し管理するための、pde4モジュレーターの使用方法及びpde4モジュレーターを含む組成物 |
BRPI0418800A (pt) * | 2004-05-05 | 2007-10-16 | Celgene Corp | métodos de tratamento ou prevenção, e de controle, de uma doença mieloproliferativa, de redução ou prevenção de um efeito adverso, de aumento da eficácia terapêutica de um tratamento de doença mieloproliferativa, composição farmacêutica, e, kit |
MXPA06012698A (es) * | 2004-05-05 | 2007-02-14 | Celgene Corp | Metodos y composiciones que utilizan farmacos inhibidores de citocina selectiva para el tratamiento y manejo de canceres y otras enfermedades. |
ITMI20041113A1 (it) * | 2004-06-01 | 2004-09-01 | Antibioticos Spa | Processo per la sintesi della talidomide |
WO2006028964A1 (en) * | 2004-09-03 | 2006-03-16 | Celgene Corporation | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines |
US20070190070A1 (en) * | 2004-09-03 | 2007-08-16 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
AU2005302523A1 (en) * | 2004-10-28 | 2006-05-11 | Celgene Corporation | Methods and compositions using PDE4 modulators for treatment and management of central nervous system injury |
US7465804B2 (en) | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
KR101342241B1 (ko) | 2005-06-30 | 2013-12-16 | 셀진 코포레이션 | 4-아미노-2-(2,6-디옥소피페리딘-3-일)이소인돌린-1,3-디온 화합물의 제조 방법 |
US20080138295A1 (en) * | 2005-09-12 | 2008-06-12 | Celgene Coporation | Bechet's disease using cyclopropyl-N-carboxamide |
CA2621949A1 (en) | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
CN1939922B (zh) * | 2005-09-27 | 2010-10-13 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3,4-c]吡咯-4,6-二酮衍生物 |
GB0522460D0 (en) * | 2005-11-03 | 2005-12-14 | Prendergast Patrick T | Composition and method for the treatment of avian influenza |
US7687526B2 (en) | 2006-09-07 | 2010-03-30 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
EP2064193A1 (de) | 2006-09-07 | 2009-06-03 | Amgen, Inc | Heterozyklische gpr40-modulatoren |
CN101147743B (zh) * | 2006-09-19 | 2010-10-06 | 浙江海正药业股份有限公司 | 人参皂甙Compound-K在制药中的应用 |
CN101186611B (zh) * | 2006-11-15 | 2011-05-18 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的吡咯啉-2-酮衍生物及其制备和应用 |
US7750048B2 (en) | 2006-11-15 | 2010-07-06 | Janssen Pharmaceutica Nv | GPR40 agonists |
CA2683751C (en) | 2007-04-16 | 2013-01-08 | Amgen Inc. | Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators |
BRPI0818253A2 (pt) | 2007-10-10 | 2015-04-07 | Amgen Inc | Moduladores de gpr40 bifenil substituídos |
JP2011515341A (ja) | 2008-03-06 | 2011-05-19 | アムジエン・インコーポレーテツド | 代謝障害の治療に有用な立体配座的に制限されたカルボン酸誘導体 |
US8748462B2 (en) | 2008-10-15 | 2014-06-10 | Amgen Inc. | Spirocyclic GPR40 modulators |
WO2010093588A1 (en) | 2009-02-10 | 2010-08-19 | Celgene Corporation | Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis |
CA2794096A1 (en) | 2010-04-07 | 2011-10-13 | Celgene Corporation | Methods for treating respiratory viral infection |
CN103068812A (zh) | 2010-06-09 | 2013-04-24 | 基因里克斯(英国)有限公司 | 沙利度胺晶型及其制备方法 |
CN103026229B (zh) | 2010-06-15 | 2016-03-30 | 细胞基因公司 | 用于治疗银屑病的生物标志物 |
GB201018171D0 (en) | 2010-10-28 | 2010-12-08 | Givaudan Sa | Organic compounds |
CA2829570C (en) | 2011-03-11 | 2019-05-07 | Celgene Corporation | Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses |
WO2014107622A1 (en) | 2013-01-07 | 2014-07-10 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
JP6513095B2 (ja) | 2014-01-03 | 2019-05-15 | ユニバーシティ オブ サザン カリフォルニア | ヘテロ原子含有デオキシウリジントリホスファターゼ阻害剤 |
US20170087129A1 (en) | 2014-05-16 | 2017-03-30 | Celgene Corporation | Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators |
US10577321B2 (en) | 2015-07-08 | 2020-03-03 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
EP3319939A1 (de) | 2015-07-08 | 2018-05-16 | CV6 Therapeutics (NI) Limited | Hydantoinhaltige desoxyuridin-triphosphatase-inhibitoren |
US10544105B2 (en) | 2015-07-08 | 2020-01-28 | Cv6 Therapeutics (Ni) Limited | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage |
WO2017006271A1 (en) | 2015-07-08 | 2017-01-12 | University Of Southern California | Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage |
CN114948963A (zh) | 2015-10-21 | 2022-08-30 | 大冢制药株式会社 | 蛋白激酶抑制剂苯并内酰胺化合物 |
US10682336B2 (en) | 2015-10-21 | 2020-06-16 | Amgen Inc. | PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS) |
US11395820B2 (en) * | 2016-03-16 | 2022-07-26 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Small molecules against cereblon to enhance effector t cell function |
US10829457B2 (en) | 2016-11-23 | 2020-11-10 | Cv6 Therapeutics (Ni) Limited | Nitrogen ring linked deoxyuridine triphosphatase inhibitors |
US11168059B2 (en) | 2016-11-23 | 2021-11-09 | Cv6 Therapeutics (Ni) Limited | Amino sulfonyl compounds |
US11174271B2 (en) | 2016-11-23 | 2021-11-16 | Cv6 Therapeutics (Ni) Limited | 6-membered uracil isosteres |
WO2018098206A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
WO2018098207A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
MX2019007434A (es) | 2016-12-21 | 2019-08-16 | Biotheryx Inc | Derivados de tienopirrol para uso en seleccion como diana de proteinas, composiciones, metodos y usos de los mismos. |
US11247984B2 (en) | 2017-01-05 | 2022-02-15 | Cv6 Therapeutics (Ni) Limited | Uracil containing compounds |
GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
US10513515B2 (en) | 2017-08-25 | 2019-12-24 | Biotheryx, Inc. | Ether compounds and uses thereof |
EP3679026A1 (de) * | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Glutarimid |
CN107698484B (zh) * | 2017-11-13 | 2020-05-19 | 广东中科药物研究有限公司 | 一种来那度胺的衍生物的制备方法与应用 |
JP2021522315A (ja) | 2018-04-17 | 2021-08-30 | 天津合美医▲薬▼科技有限公司Tianjin Hemay Pharmaceutical Co., Ltd. | イソインドール誘導体 |
US11730726B2 (en) | 2018-07-11 | 2023-08-22 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Dimeric immuno-modulatory compounds against cereblon-based mechanisms |
AU2019309894A1 (en) | 2018-07-27 | 2021-01-28 | Biotheryx, Inc. | Bifunctional compounds as CDK modulators |
US11897930B2 (en) | 2020-04-28 | 2024-02-13 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
CN112724024A (zh) * | 2021-01-19 | 2021-04-30 | 宁波酶赛生物工程有限公司 | 一种r-苄基苯乙胺的合成方法 |
WO2022187423A1 (en) * | 2021-03-03 | 2022-09-09 | The Regents Of The University Of Michigan | Cereblon ligands |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB768821A (en) * | 1954-05-17 | 1957-02-20 | Gruenenthal Chemie | Novel products of the amino-piperidine-2, 6-dione series |
GB1036694A (en) * | 1964-03-03 | 1966-07-20 | Wyeth John & Brother Ltd | Substituted aminocarboxylic acid derivatives and compositions containing such derivatives |
GB1030030A (en) * | 1964-12-28 | 1966-05-18 | Vismara Francesco Spa | Derivatives of phthalimide |
AT278739B (de) * | 1966-11-08 | 1970-02-10 | Kwizda Fa F Johann | Verfahren zur Herstellung von neuen Anhydriden und Imiden substituierter Dicarbonsäuren |
US3553217A (en) * | 1968-10-18 | 1971-01-05 | Aldrich Chem Co Inc | 2-(quinolinimido)glutarimide |
CH554833A (de) * | 1970-04-09 | 1974-10-15 | Ciba Geigy Ag | Verfahren zur herstellung von neuen (beta)-amino-(beta)-phenylpropionsaeuren, -estern und-amiden. |
CH554837A (de) * | 1970-04-09 | 1974-10-15 | Ciba Geigy Ag | Verfahren zur herstellung von neuen (beta)-amino-(beta)-phenylpropionsaeuren, -estern und -amiden. |
US4918193A (en) * | 1989-01-11 | 1990-04-17 | Burzynski Stanislaw R | Methods for preparing 3-[N-phenyl-acetylaminopiperidine]-2,6-dion |
GB9000644D0 (en) * | 1990-01-11 | 1990-03-14 | Erba Carlo Spa | New ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds |
GB9109645D0 (en) | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
AU1531492A (en) * | 1991-02-14 | 1992-09-15 | Rockefeller University, The | Method for controlling abnormal concentration tnf alpha in human tissues |
-
1993
- 1993-10-20 US US08/140,237 patent/US5463063A/en not_active Expired - Lifetime
-
1994
- 1994-07-01 DK DK94921439T patent/DK0706521T3/da active
- 1994-07-01 CA CA002626178A patent/CA2626178A1/en not_active Abandoned
- 1994-07-01 CZ CZ9610A patent/CZ1096A3/cs unknown
- 1994-07-01 AT AT94921439T patent/ATE225344T1/de active
- 1994-07-01 SK SK1665-95A patent/SK166595A3/sk unknown
- 1994-07-01 CA CA002166315A patent/CA2166315C/en not_active Expired - Fee Related
- 1994-07-01 PL PL94312386A patent/PL180377B1/pl not_active IP Right Cessation
- 1994-07-01 PT PT00200491T patent/PT1004580E/pt unknown
- 1994-07-01 AT AT00200491T patent/ATE348809T1/de not_active IP Right Cessation
- 1994-07-01 JP JP50364895A patent/JP3971794B2/ja not_active Expired - Fee Related
- 1994-07-01 PT PT00200498T patent/PT1004572E/pt unknown
- 1994-07-01 ES ES00200491T patent/ES2278574T3/es not_active Expired - Lifetime
- 1994-07-01 PT PT00200492T patent/PT1004581E/pt unknown
- 1994-07-01 NZ NZ329258A patent/NZ329258A/xx not_active IP Right Cessation
- 1994-07-01 ES ES00200492T patent/ES2226696T3/es not_active Expired - Lifetime
- 1994-07-01 NZ NZ268812A patent/NZ268812A/en not_active IP Right Cessation
- 1994-07-01 DK DK00200498T patent/DK1004572T3/da active
- 1994-07-01 DK DK00200491T patent/DK1004580T3/da active
- 1994-07-01 DE DE69434029T patent/DE69434029T2/de not_active Expired - Lifetime
- 1994-07-01 NZ NZ329259A patent/NZ329259A/en not_active IP Right Cessation
- 1994-07-01 CZ CZ2003663A patent/CZ294444B6/cs not_active IP Right Cessation
- 1994-07-01 AT AT00200492T patent/ATE277036T1/de active
- 1994-07-01 ES ES94921439T patent/ES2184765T3/es not_active Expired - Lifetime
- 1994-07-01 EP EP04077075A patent/EP1477486A3/de not_active Withdrawn
- 1994-07-01 ES ES00200498T patent/ES2258956T3/es not_active Expired - Lifetime
- 1994-07-01 AT AT00200498T patent/ATE319678T1/de not_active IP Right Cessation
- 1994-07-01 WO PCT/US1994/007411 patent/WO1995001348A2/en active IP Right Grant
- 1994-07-01 DE DE69434645T patent/DE69434645T2/de not_active Expired - Fee Related
- 1994-07-01 PT PT94921439T patent/PT706521E/pt unknown
- 1994-07-01 EP EP00200492A patent/EP1004581B1/de not_active Expired - Lifetime
- 1994-07-01 EP EP00200491A patent/EP1004580B1/de not_active Expired - Lifetime
- 1994-07-01 DE DE69434895T patent/DE69434895T2/de not_active Expired - Fee Related
- 1994-07-01 HU HU9600003A patent/HUT75312A/hu unknown
- 1994-07-01 DE DE69431480T patent/DE69431480T2/de not_active Expired - Lifetime
- 1994-07-01 EP EP00200498A patent/EP1004572B1/de not_active Expired - Lifetime
- 1994-07-01 EP EP94921439A patent/EP0706521B1/de not_active Expired - Lifetime
- 1994-07-01 DK DK00200492T patent/DK1004581T3/da active
- 1994-07-01 AU AU72167/94A patent/AU687843B2/en not_active Ceased
- 1994-07-01 CA CA2531868A patent/CA2531868C/en not_active Expired - Lifetime
- 1994-07-01 RU RU96102001/04A patent/RU2174516C2/ru not_active IP Right Cessation
- 1994-07-01 KR KR1019960700005A patent/KR100401290B1/ko not_active IP Right Cessation
-
1995
- 1995-12-29 FI FI956362A patent/FI114984B/fi not_active IP Right Cessation
-
2000
- 2000-08-10 HK HK00104989A patent/HK1025769A1/xx not_active IP Right Cessation
- 2000-08-10 HK HK00104990A patent/HK1025770A1/xx not_active IP Right Cessation
- 2000-08-10 HK HK00104991A patent/HK1025765A1/xx not_active IP Right Cessation
-
2004
- 2004-04-27 FI FI20040593A patent/FI20040593A/fi not_active Application Discontinuation
-
2006
- 2006-02-16 JP JP2006039629A patent/JP2006131647A/ja active Pending
- 2006-02-16 JP JP2006039624A patent/JP4461107B2/ja not_active Expired - Fee Related
- 2006-02-16 JP JP2006039637A patent/JP2006188530A/ja active Pending
- 2006-02-16 JP JP2006039633A patent/JP2006188529A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1004572T3 (da) | Aminer som inhibitorer af TNF alpha | |
DE69626513T2 (de) | Imidazolverbindungen | |
ES2121342T3 (es) | Monomeros a base de urea y de uretano utilizados en materiales para lentes de contacto. | |
DK0804196T3 (da) | Anvendelse af serotoninantagonister (5HT 3) til behandling af fibromyalgia | |
ATE212014T1 (de) | 4-acylaminopiperidin-n-oxyle | |
DK0739212T3 (da) | Anvendelse af interleukin-12 til forebyggelse af transplantat-vs.-værtssygdom | |
DE69226763T2 (de) | Härten von fluoroelastomeren | |
DE69113910D1 (de) | Härtbare Siloxanzusammensetzung und gehärteter Gegenstand. | |
FR2687161B1 (fr) | Compositions a base de scleroglucane et leur utilisation comme tampon de cimentation. | |
DE69111382T2 (de) | Polymerisationsinhibitor und Inhibierungsmethode für Vinylverbindungen. | |
DE69126835T2 (de) | Epoxydharz, Epoxydharzzusammensetzung und damit hergestellte gehärtete Gegenstände | |
ATE320422T1 (de) | Metalloproteinase inhibitoren | |
DE69208759T2 (de) | Salze von N-Nitrosophenylhydroxylamin | |
KR900700136A (ko) | 특정 paf 길항제/항히스타민제 조성물 | |
DK1015232T3 (da) | Fremgangsmåde til behandling af emner med plastic | |
DE69517336D1 (de) | Verwendung schiefer implantation beim bilden der basis von bipolaren transistoren | |
DK1017377T3 (da) | Anvendelse af 6,7-substituerede 2-aminotetraliner til behandling af af cytokin fremkaldte inflammatoriske tilstande | |
FR2703066B1 (fr) | Procédé d'intégration en milieu écologique et compositions pour sa mise en Óoeuvre. |